# US 2004/0204561 A1 · Peptide aggregates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0204561 A1
- Document ID: US20040204561A1
- Status: Published application
- Kind: A1
- Application number: 10/635,838
- Filed: 2003-08-06
- Published: 2004-10-14
- Earliest claimed: 2002-08-06
- Inventors: Jeffrey J. Ellison
- Web page: https://patentgrep.com/patent/US20040204561A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 49/14: Peptides, e.g. proteins
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- G01R 33/281: {Means for the use of in vitro contrast agents (G01R33/282 takes precedence; involving use of a contrast agent in MR imaging G01R33/5601; in vivo contrast agents A61K49/0002)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01R: MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES (indicating correct tuning of resonant circuits H03J3/12)

## Abstract

Disclosed are peptide aggregates that include assembling peptides optionally linked to metal binding moieties and/or target binding moieties. Also disclosed are methods of using such peptide aggregates for magnetic resonance imaging.

## Claims

### Claim 1

A peptide aggregate comprising two or more assembling peptides, wherein at least one of said assembling peptides comprises a metal binding moiety.

### Claim 2 (depends on 1)

The aggregate of claim 1, wherein the hydrodynamic radius of said aggregate is 2 nm to 500 nm.

### Claim 3 (depends on 1)

The aggregate of claim 1, wherein at least one of said assembling peptides comprises a target binding moiety having an affinity for a target.

### Claim 4 (depends on 3)

The aggregate of claim 3, wherein said target is selected from the group consisting of HSA, fibrin, collagen, decorin, and elastin.

### Claim 5 (depends on 1)

The aggregate of claim 1, wherein said metal binding moiety is an organic chelating ligand.

### Claim 6 (depends on 5)

The aggregate of claim 5, wherein said organic chelating ligand is selected from the group consisting of DTPA, DOTA, DOTP, DO3A, DOTAGA, and NOTA.

### Claim 7 (depends on 1)

The aggregate of claim 1, wherein said two or more assembling peptides independently comprise an amino acid sequence selected from the group consisting of:
3 AEAEAKAKAEAEAKAK; (SEQ ID NO: 1) MDYEIKFH; (SEQ ID NO: 2) MDYNIQFH; (SEQ ID NO: 3) MDYKFKFN; (SEQ ID NO: 4) NFDLNLD; (SEQ ID NO: 5) EIQFEID; (SEQ ID NO: 6) NIDFQFD; (SEQ ID NO: 7) DLQLQIR; (SEQ ID NO: 8) DIEIEIR; (SEQ ID NO: 9) EVDIEIR; (SEQ ID NO: 10) RVQVHIH; (SEQ ID NO: 11) RVHIQLN; (SEQ ID NO: 12) RVHINLD; (SEQ ID NO: 13) KVDFHVN; (SEQ ID NO: 14) HIKVDFH; (SEQ ID NO: 15) QLKFHVN; (SEQ ID NO: 16) DVEVKMH; (SEQ ID NO: 17) ELQIDMH; (SEQ ID NO: 18) EFNLKMH; (SEQ ID NO: 19) DLENLLEKFEQLIK; (SEQ ID NO: 20) KLNHVVQELQELVQ; (SEQ ID NO: 21) KLKNLLNDFEDLIN; (SEQ ID NO: 22) NVQQLLKKLQQMIQ; (SEQ ID NO: 23) EIEDLLQKLQELME; (SEQ ID NO: 24) KIQKIIEKVNELMQ; (SEQ ID NO: 25) DLHNLINKLDDVMQ; (SEQ ID NO: 26) KMHDLIDDLHHLLN; (SEQ ID NO: 27) KLNDLLEDLQEVLK; (SEQ ID NO: 28) HLQNVIEDIHDFMQ; (SEQ ID NO: 29) KLQEMMKEFQQVLD; (SEQ ID NO: 30) and NIKEIFHHLEELVH. (SEQ ID NO: 31)

### Claim 8 (depends on 5)

The aggregate of claim 5, wherein said organic chelating ligand is bound to a paramagnetic metal ion.

### Claim 9 (depends on 8)

The aggregate of claim 8, wherein said paramagnetic metal ion is Gd (III).

### Claim 10 (depends on 1)

The aggregate of claim 1, wherein said assembling peptides are self-assembling peptides.

### Claim 11 (depends on 7)

The aggregate of claim 7, wherein said sequence is modified at the C-terminus by an acidic moiety.

### Claim 12 (depends on 11)

The aggregate of claim 11, wherein said acidic moiety is selected from the group consisting of a linear diacid, glutamic acid, aspartic acid, phthalic acid, isophthalic acid, and terephthalic acid.

### Claim 13

An assembling peptide having a structure: P—(C)n, wherein P refers to an assembling peptide amino acid sequence, C refers to an organic chelating ligand, and n can be 1 to 10.

### Claim 14 (depends on 13)

The assembling peptide of claim 13, further comprising a target binding moiety.

### Claim 15

An assembling peptide comprising a target binding moiety.

### Claim 16

An assembling peptide comprising an amino acid sequence selected from the group consisting of:
4 AEAEAKAKAEAEAKAK; (SEQ ID NO: 1) MDYEIKFH; (SEQ ID NO: 2) MDYNIQFH; (SEQ ID NO: 3) MDYKFKFN; (SEQ ID NO: 4) NFDLNLD; (SEQ ID NO: 5) EIQFEID; (SEQ ID NO: 6) NIDFQFD; (SEQ ID NO: 7) DLQLQIR; (SEQ ID NO: 8) DIEIEIR; (SEQ ID NO: 9) EVDIEIR; (SEQ ID NO: 10) RVQVHIH; (SEQ ID NO: 11) RVHIQLN; (SEQ ID NO: 12) RVHINLD; (SEQ ID NO: 13) KVDFHVN; (SEQ ID NO: 14) HIKVDFH; (SEQ ID NO: 15) QLKFHVN; (SEQ ID NO: 16) DVEVKMH; (SEQ ID NO: 17) ELQIDMH; (SEQ ID NO: 18) EFNLKMH; (SEQ ID NO: 19) DLENLLEKFEQLIK; (SEQ ID NO: 20) KLNHVVQELQELVQ; (SEQ ID NO: 21) KLKNLLNDFEDLIN; (SEQ ID NO: 22) NVQQLLKKLQQMIQ; (SEQ ID NO: 23) EIEDLLQKLQELME; (SEQ ID NO: 24) KIQKIIEKVNELMQ; (SEQ ID NO: 25) DLHNLINKLDDVMQ; (SEQ ID NO: 26) KMHDLIDDLHHLLN; (SEQ ID NO: 27) KLNDLLEDLQEVLK; (SEQ ID NO: 28) HLQNVIEDIHDFMQ; (SEQ ID NO: 29) KLQEMMKEFQQVLD; (SEQ ID NO: 30) and NIKEIFHHLEELVH; (SEQ ID NO: 31)
wherein said assembling peptide further comprises a target binding moiety, a metal binding moiety, or both.

### Claim 17

An assembling peptide selected from the group consisting of EP1272L, EP1593L, EP1594L, EP1595, and EP1596.

### Claim 18

A method for MR imaging of a target comprising:
i) administering to a patient a peptide aggregate, said peptide aggregate comprising at least one assembling peptide comprising a metal binding moiety bound to a paramagnetic metal ion and at least one assembling peptide comprising a target binding moiety having an affinity for said target; and
ii) subjecting said patient to MR imaging.

### Claim 19

A method for MR imaging comprising:
i) administering to a patient a peptide aggregate, said peptide aggregate comprising at least one assembling peptide comprising a metal binding moiety bound to a paramagnetic metal ion; and
ii) subjecting said patient to MR imaging.

### Claim 20

A method for MR imaging of a target, comprising:
i) administering to a patient at least two assembling peptides, said at least two assembling peptides capable of forming a peptide aggregate after administration to said patient, wherein at least one of said two assembling peptides comprises a metal binding moiety bound to a paramagnetic metal ion and at least one of said two assembling peptides comprises a target binding moiety having an affinity for said target; and
ii) subjecting said patient to MR imaging.
